首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.
【24h】

Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.

机译:在最初的同种异体SCT之后,使用脐带血治疗白血病的第二次清髓性异体干细胞移植(SCT)复发。

获取原文
获取原文并翻译 | 示例
           

摘要

There are many reports of second allogeneic stem cell transplantation (allo-SCT) using cord blood (CB) for graft failure after initial allo-SCT. However, the efficacy of second allo-SCT using CB for patients with leukemia relapsed after initial allo-SCT is unknown. We report the results of second allo-SCT using CB in seven adult patients with leukemia relapsed after initial allo-SCT. All patients received a myeloablative conditioning regimen including oral busulfan 16 mg/kg, intravenously fludarabine 100mg/m(2) and cyclophosphamide 120 mg/kg. All but one patient had myeloid reconstitution and four patients remain alive at between 4 and 40 months after second SCT. We conclude that second myeloablative allo-SCT using CB may be feasible in selected patients with the relatively younger age, less organ damage and longer time interval between first and second allo-SCT.
机译:有许多关于第二次同种异体干细胞移植(allo-SCT)的报道,这些移植是在最初的allo-SCT之后使用脐带血(CB)进行的移植失败。然而,第二次使用CB的allo-SCT对最初的allo-SCT后复发的白血病患者的疗效尚不清楚。我们报告了使用CB在7名成年白血病成年白血病患者中进行第二次异源SCT的结果,这些患者在最初的异源SCT之后复发。所有患者均接受清髓治疗,包括口服白消安16 mg / kg,静脉注射氟达拉滨100mg / m(2)和环磷酰胺120 mg / kg。在第二次SCT后的4至40个月之间,除一名患者外,所有患者均发生了髓样重构,四名患者仍存活。我们得出的结论是,对于年龄相对较小,器官损伤较少且第一和第二同种异体SCT之间时间间隔较长的某些患者,使用CB进行第二种清髓同种异体SCT可能是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号